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Background /aim: Acromegaly is a rare chronic endocrine disorder, the active form of which is associated with an increased risk of
cardiovascular and metabolic disease. Therefore, early diagnosis and treatment of cardiovascular diseases in acromegaly patients are
important in terms of morbidity and mortality. The aim of this study was to determine whether the visceral adiposity index (VAI),
lipid accumulation product (LAP), and plasma atherogenic index (PAI) are early cardiovascular risk markers in patients with active
acromegaly.
Materials and methods: The study included 45 patients newly diagnosed with acromegaly and 45 age–sex matched healthy control
subjects. The VAI, LAP, and PAI values were calculated, and carotid artery intima media thickness (CIMT) was measured in both the
patients and control groups.
Results: The PAI, VAI, LAP, and CIMT values were significantly higher in patients with acromegaly compared with the control subjects
(p < 0.004, p < 0.027, p <0.012, and p <0.001, respectively). In the patient group, a significant positive correlation was found between the
growth hormone (GH) and insulin-like growth factor I (IGF-I) levels, and between the VAI, LAP and PAI values. A significant positive
correlation was determined between CIMT and LAP values in the patient group.
Conclusion: CIMT is a noninvasive method used to show early atherosclerosis. However, it is operator dependent. Therefore, VAI, LAP
and PAI can be used as noninvasive, simple measurement methods to evaluate early atherosclerosis in patients with acromegaly.
Key words: Acromegaly, atherosclerosis markers, plasma atherogenic index, lipid accumulation product, visceral adiposity index,
cardiovascular disease

1. Introduction
Acromegaly is a rare chronic endocrine disease,
characterized by excessive growth hormone (GH) and
increased insulin-like growth factor I (IGF-I) levels. In
the vast majority of cases, the causative agent is generally
a GH-secreting pituitary adenoma [1]. Overproduction
of GH and IGF-I levels are associated with multiple
comorbidities of various systemic (cardiovascular,
hypertension, obstructive sleep apnea, colon polyposis,
etc.) and metabolic complications [2]. In acromegaly, there
are changes in protein, carbohydrate and fat metabolism
due to excessively increased levels of GH and IGF-I [3,4].
Cardiovascular diseases are the primary cause of death in
acromegaly, especially when it is active and uncontrolled
[5]. This condition is further exacerbated in comorbid

conditions such as insulin resistance, type 2 diabetes,
dyslipidemia and hypertension [4–7].
The visceral adipocyte index (VAI) is a recently
developed mathematical index, calculated using simple,
noninvasive parameters [(waist circumference (WC), body
mass index (BMI), serum triglycerides (TG), high density
lypoproteine cholesterol (HDL-C) levels )]. Studies have
shown that it is significantly correlated with cardiovascular
risk and metabolic syndrome [8], and similar studies have
been conducted on active acromegaly patients [9,10].
Lipid accumulation product (LAP) is calculated based on
the measurement of serum TG levels and WC [11] and has
been used to predict cardiovascular risk in different disease
populations (type 2 diabetes mellitus, insulin resistance,
polycystic ovary syndrome) [12]. The plasma atherogenic
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index (PAI) is calculated using plasma TG and C levels,
and studies have shown it to be an important indicator of
atherosclerosis and coronary artery disease [13–15]. The
measurement of carotid artery intima media thickness
(CIMT) is a reliable, noninvasive, and simple method for
the detection of subclinical atherosclerosis in patients with
acromegaly [16].
The aim of this study was to investigate whether VAI,
LAP and PAI may be useful markers in the evaluation of
subclinical atherosclerosis in patients newly diagnosed
with active acromegaly.
2. Materials and methods
This retrospective study, included 45 patients newly
diagnosed with acromegaly patients (26 females, 19 males;
average age 49.8 ± 11.7 years), and 45 age-sex matched
healthy control subjects (28 females, 17 males; average age
46.2 ± 5.2 years) were included in this study. Exclusion
criteria were defined as the presence of mixed hormone
secreting adenoma, a history of acromegaly therapy,
the presence of one or more anterior pitiutary hormone
deficiencies, or severe hypertriglyceridemia. Disease
activity was determined according to plasma GH and
IGF-I levels. Pituitary magnetic resonance imaging (MRI)
scan was performed in all patients to detect pituitary
adenoma.
Approvel for the study was granted by the local ethics
committee and all participants provided informed consent
before participation. This study was carried out in the
Department of Endocrinology and Metabolism Diseases
at the Dışkapı Training and Research Hospital in Ankara.
The diagnosis of acromegaly was based on the
Endocrine Society Clinical Practice Guidelines [17] as
follows: 1) typical acromegaly clinical manifestations, 2)
lowest serum GH concentration of > 1 ng/mL after a 75-g
oral glucose tolerance test (OGTT) or fasting GH value of
> 2.5 ng/mL, 3) serum IGF-I levels above the normal ageadjusted range, and 4) contrast -enhanced MRI showing a
pituitary tumor in the sellar area.
All blood samples were drawn at 8 a.m. glycated
haemoglobin (HbA1c) was measured using the highperformance liquid chromatography (HPLC) method.
The IGF-I and GH concentrations were measured using
chemiluminescence on an IMMULITE 2000 Xpi device
(Siemens Health-care Diagnostics Inc). Serum IGF-I
levels were compared with the age-sex-adjusted normal
reference values. Plasma levels of TG, HDL, low-density
lipoprotein (LDL), glucose, and creatinine were evaluated
using an automated chemistry analyzer (Aeroset, Abbott,
Holliston, MN, USA) using commercially available kits
(Abbott, USA). LDL-C levels were calculated using the
Friedewald formula (TC=LDL+HDL+TG/5 ).

2.1. Anthropometric measurements
All measurements were performed by the same researcher.
The anthropometric measurements included height,
weight, and waist and hips circumference. BMI was
calculated by dividing body weight (kg) by the square of
height (m2). WC was measured at the midpoint between
the iliac crests and the lowest rib while standing. Hip
circumference was measured at the widest part of the hips.
The average of these two values were calculated as the
waist-hip-ratio (WHR).
VAI (TG and HDL-C levels expressed in millimoles
per liter), and LAP were calculated to evaluate abdominal
adiposity [8,11]. PAI values were calculated using the log10
TG/HDL formula [13]. The following formulas were used:
VAI (males) = [WC (cm) / 36.58 + (1.88 × BMI)] × (TG
/ 1.03) × (1.31 / HDL-K)
VAI (females) = [WC (cm) / (36.58 + (1.88 × BMI)] ×
(TG / 0.81) × (1.52 / HDL-K)
LAP (males) = (WC (cm) – 65) × TG
LAP (females) = (WC (cm) – 58) × TG
PAI = log10 TG / HDL formula
Patients diagnosed with diabetes mellitus, dyslipidemia,
metabolic syndrome, obesity,
systolic or diastolic
hypertension for the first time at the time of the diagnosis
of acromegaly did not receive any specific treatment before
the anthropometric measurements.
2.2. Measurement of CIMT
The CIMT was derived from a noninvasive ultrasound
of the common carotid arteries, using a high-resolution
B-mode ultrasound machine (EUB 7000 HV; Hitachi,
Tokyo, Japan) with a 13 MHz linear array transducer.
CIMT was defined as the distance between the bloodintima and media-adventitia boundaries on B-mode
imaging. Three measurements were performed from 1 cm
proximal to both main carotid artery bifurcations, and
CIMT measurements were taken only from the posterior
wall. The average CIMT was calculated from the average
of three measurements taken from both arteries. All these
examinations were performed by one of the authors (M.O).
2.3. Statistical analysis
Statistical analyses were performed using SPSS software
(version 23.0, SPSS, IBM Corporation, NY, USA). The
Kolmogorov–Smirnov test was applied to assess conformity
of the data to normally distribution. Categorical data
were summarized as frequency and percentage (%). All
continuous variables as mean ± standard deviation (SD)
values for normally distributed variables and as median
(range) for nonnormally distributed variables. The
ındependent samples t-test was used to compare continuous
variables with normal distribution, and the Mann–
Whitney U test for nonnormally distributed variables. A
associations between categorical variables were examined
using chi-square analysis, and the association between
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numerical variables with Pearson’s correlation analysis.
Results were given with a 95 % confidence interval and a
value of p < 0.05 was considered statistically significant.
3. Results
The demographic, anthropometric and biochemical
characteristics of the patients newly diagnosed with
acromegaly and the control subjects are shown in Table
1. The acromegaly group (n=45) comprised of 26 females
and 19 male with a mean age of 49.8 ± 11.7 years. The
control group (n= 45) comprised 28 female, and 17 males
with a mean age of 46.2 ± 5.2 years. Routine biochemical
and hormonal parameters including fasting blood glucose
(FBG), HbA1c, TC, LDL-C, TG, GH, and IGF-I levels
were significantly elevated in the patients with acromegaly
compared with the control subjects. Significantly higher
anthropometric parameters of WC, weight and BMI were

determined in the acromegaly group than in the control
group (p < 0.004, p <0.001, and p < 0.001, respectively).
VAI values were significantly elevated in acromegalic
patients compared to the control subjects [4.7 (1.6725.95), 2.6 (0.96-15.3), p < 0.027, respectively]. LAP values
were significantly elevated in patients with acromegaly
compared with the control subjects [ 41.3 (13.77–339.1),
28.2 (1.89–174.9), p < 0.012, respectively]. PAI values
were significantly elevated in patients with acromegaly
when compared with control subjects [0.49 (–0.02–1.13),
0.2 (–0.23–1.05), p < 0.004, respectively]. WHR values
were significantly elevated in patients with acromegaly
compared with the control subjects (0,59 ± 0,08, 0,53 ±
0,08, p<0.004, respectively). CIMT levels were significantly
elevated in the acromegaly group when compared with
the control group (0.77 ± 0.13, 0.51 ± 0.11, p < 0.001,
respectively).

Table 1. Demographic, metabolic and laboratory findings of the acromegaly and control
groups.
Acromegaly (n = 45)

Control (n = 45)

p-value

Sex (female/ male)

26/19

28/17

0.66

Age(years)

49.8 ± 11.7

46.2+5.2

0.08

Height (cm)

165.3 ± 8.4

165.6 ± 8.4

0.89

Weight(kg)

84 ± 17

73 ± 12

0.001

BMI (kg/ m2 )

31 ± 6.6

26,6 ± 4.4

0.001

WC(cm)

97.6 ± 13.8

88 ± 13

0.004

HC(cm)

108 ± 15.1

105.4 ± 9.2

0.42

VAI

2.6 (0.96-15.3)

4.7 (1.67-25.95)

0.027

PAI

0.49 (-0.02-1.13)

0.2 (-0.23-1.05)

0.004

LAP

41.3 (13.77-339.1)

28.2 (1.89-174.9)

0.012

WHR

0.59 ± 0.08

0.53 ± 0.08

0.004

IGF-I

559.5 (329–1581)

-

-

GH

8.4 (1.59–55.7)

-

-

FBG (mg/dL)

113.6 ± 34

92.1 ± 8.5

<0.001

HbA1c (%)

6.7 ± 1.9

5.4 ± 0.4

<0.001

TC (mg/dL)

185.1 ± 31

170 ± 33.9

0.04

LDL-C (mg/dL)

126.9 ± 24.2

108.5 ± 28.9

0.002

HDL-C (mg/dL)

46.3 ± 12.1

49.8 ± 15.1

0.26

TG (mg/dL)

128 (61–527)

82.6 (27–397)

0.001

CIMT(mm)

0.77 ± 0.13

0.51 ± 0.11

<0.001

Abbreviations: WC, waist circumference; HC, hip circumference; BMI, body mass index;
CIMT, carotid intima-media thickness; FPG, fasting blood glucose; TC, total cholesterol;
TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density
lipoprotein cholesterol; HbA1c, heamoglobine A1c; GH, growth hormone; IGF-I,
insulin-like growth factor I; PAI, plasma atherogenic index; LAP, lipid accumulation
product; VAI, visceral adiposity index; WHR, waist-hip ratio.
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The correlations between serum GH, IGF-I, CIMT and
laboratory and anthropometric parameters of all the study
participants are shown in Table-2.
In the acromegaly group a significant positive
correlation was found between CIMT and HbA1c (r =
0.42, p = 0.002), GH (r = 0.76, p < 0.001), IGF-I (r = 0.698,
p < 0.001), LAP (r = 0.372, p = 0.006) and WHR (r = 0.506,
p <0.001). A significant positive correlation was found
between GH and HbA1c (r = 0.604, p < 0.001), IGF-I (r =
0.763, p < 0.001), VAI (r = 0.29 p =0.012 ), PAI ( r =0.357,
p<0.001 ), LAP ( r =0,288, p =0.013 ) and WHR ( r=0.243,
p = 0.037) in patients with acromegaly. A significant
positive correlation was found between IGF-I and HbA1c
(r = 0.537, p < 0.001), GH (r = 0.763 , p < 0.001), VAI (r
= 0.307, p = 0.008), PAI ( r = 0.344, p = 0.002 ), LAP (r =
0.300, p = 0.009) and WHR (r = 0.232, p = 0.04) in patients
newly diagnosed with acromegaly patients.
4. Discussion
In patients with active acromegaly, mortality is generally
significantly higher than in the general population [18].
Mortality rates are increased especially by cardiovascular
diseases (60% cardiovascular, 25% respiratory disease,
and 10% malignancy) [5]. Acromegalic cardiomyopathy
is disease specific, and it is associated with the duration
of the disease. It depends on the long-term GH / IGF-I
effect [19]. High serum GH levels are a more important
independent risk factor in mortality than IGF-1 levels [20].
The results of this study showed that, traditional
biochemical and anthropometric cardiovascular risk
factors, such as FBG, HbA1c, TC, LDL-C, TG, weight,
BMI, and WC were significantly higher in patients with
active acromegaly compared to control subjects.
In this study VAI, LAP, PAI and CIMT levels were
evaluated in patients with newly diagnosed acromegaly
and in control subjects.
Recent studies have shown that high VAI levels are
a strong independent risk factor associated with the
development of cardiovascular and cerebrovascular events.

It has also been emphasized that VAI is a good indicator
for the development of diabetes [8,21].
In a recent study, Ciresi A, et al concluded that VAI is
associated with disease activity, and may be a useful marker
for early metabolic risk in patients with newly diagnosed
active acromegaly [9] and is independently influenced by
GH levels [9].
It has been suggested that VAI may be a useful marker
for the evaluation of cardiometabolic risk in postmenaposal
patients with active acromegaly [10]. Giordano C et al.
reported that active acromegaly is strongly associated with
visceral adiposity dysfunction, and VAI indirectly shows
adipose tissue dysfunction [22]. In another study, VAI and
CIMT were found to be correlated independently of other
cardiovascular risk factors, and it was concluded that the
calculation of VAI may provide a beter estimation of early
atherosclerosis than the insulin resistance marker [23].
In this study, similar to the literature, we found higher
VAI levels in the active acromegalic patients than control
subjects. There was statistically significant positive
correlations between GH / IGF-I and VAI levels (r = 0.29,
p = 0.012, r = 0.307, p = 0.008, respectively). High levels of
VAI in our study can also be attributed to the findings of
metabolic syndrome parameters. In this study, there was
no correlation between CIMT and VAI levels.
In our study, similar to the literature, VAI levels may
be associated with disease activity in active acromegaly.
VAI may be a marker for early atherosclerosis in active
acromegalic patients.
LAP is a new index to predict the deposition of central
lipid tissue and is used in detection of metabolic syndrome.
It was shown that LAP was better than BMI in predicting
insulin resistance and cardiovascular risk [24,25]. In
another study reported that LAP was the best predictor
of metabolic syndrome, according to VAI, triglyceride to
glucose index and WHR [26].
In the present study, LAP measurements were found
significantly increased in patients with active acromegaly
than control subjects. In our results, LAP measurements

Table-2. Correlation analyses results between CIMT, GH, IGF-I and anthropometric values.
Correlation
graphic
CIMT
GH
IGF-I

HbA1c

GH

IGF-1

VAI

PAI

LAP

r value

0.42

0.716

0.698

0.204

0.182

0.372

p value

0.002

<0.001

<0.001

0.143

0.19

0.006

r value

0.604

1.000

0.763

0.29

0.357

0.288

p value

<0.001

-

<0.001

0.012

<0.001

0.013

r value

0.537

0.763

1.000

0.307

0.344

0.300

p value

<0.001

<0.001

-

0.008

0.002

0.009
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were also correlated with both CIMT, GH and IGF-I
levels. Furthermore, in this study CIMT values were
positive correlated with HBA1c levels. As a result of these
findings, we can say that LAP measurements are indirectly
related to dysglycemia and insulin resistance. And also,
in patients with acromegaly, LAP measurements may
be used as a surrogate marker for predicting subclinical
atherosclerosis.
According to many evidence, dyslipidemia is the most
important major risk factor for coronary artery disease
[27]. PAI has been found to be associated with metabolic
syndrome and obesity in many studies [28,29]. In another
study, Zhu at al. demonstrated that PAI is positively
correlated with diabetes mellitus [30]. The findings of
the studies showed that PAI is a powerful indicator of the
risk for athrosclerotic cardiovascular disease [31–33]. In
another study, PAI was found to be positively correlated
with cardiovascular diseases in postmenopausal women
[34]. PAI values differ in previous studies. This situation
is attributed to different ethnic groups in the studies [34].
In our study, PAI values were found significantly
increased in patients with active acromegaly than control
subjects. According to correlation analysis, there was
a positive correlation between the PAI and GH levels in
patients with acromegaly. And also, there was a positive
correlation between the PAI and IGF-I levels in patients
with acromegaly. There was no correlation between PAI
and CIMT levels in acromegaly patients.
CIMT level is a reliable, noninvasive and easy indicator,
which can be applied in ultrasonographic evaluations.
It could be recommended as a potential measurement
method to detect subclinical atherosclerosis, which
has been shown in many studies [35–37]. In previous
studies, higher CIMT measurements have been found in
acromegaly patients, as an indicator of early atherosclerosis
[16,38].
In this study, CIMT levels were significantly elevated in
acromegalic patients when compared with control subjects
(0.77 ± 0.13, 0.51 ± 0.11, p < 0.001, respectively). A
significant positive correlation was found between CIMT
and HbA1c (r = 0.42, p = 0.002), GH (r = 0.76, p < 0.001),
IGF-I (r = 0.698, p < 0.001), LAP (r =0.372, p = 0.006) and
WHR (r = 0.506, p < 0.001) in patients with acromegaly.

In our study, higher CIMT measurements seem to be
associated with blood glucose dysregulation, metabolic
syndrome parameters, obesity, and higher levels of GH
and IGF-I in patients with newly diagnosed acromegalic
patients.
5. Conclusion
Our study is the first study evaluating LAP and PAI
measurements in newly diagnosed acromegaly patients.
Our results show that LAP and PAI values, which are
a simple measurement method, can be used easily to
evaluate early atherosclerosis in patients with acromegaly.
According to their advantage, LAP and PAI measurements
are not operator dependent. The measurements are
performed with cheaper routine biochemical and
anthropometric data. Well-planned prospective studies
with a large number of cases are needed on this subject.
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